...
By Jake Cole
0
Share
Newsweek is a Trust Project member
See more of our trusted coverage when you search.Prefer Newsweek on Googleto see more of our trusted coverage when you search.
Healthcare is entering a period where treatment decisions are becoming increasingly individualized. Precision medicine, supported by advances in genomics, molecular profiling, and computational analysis, is influencing how clinicians diagnose disease and select therapies. Oncology has become one of the clearest examples of this evolution as researchers seek to better understand why patients with seemingly similar cancers often experience very different outcomes from the same treatment.
Artificial intelligence is adding new capabilities to this transition by helping researchers interpret increasingly complex biological data. According to Intel Market Research’s AI Biomedicine Service Market analysis, AI-enabled precision medicine solutions now account for approximately 35 percent of global digital health investment, reflecting growing interest in biomarker discovery, patient stratification, and clinical trial optimization. The report also notes increasing regulatory acceptance of AI-assisted diagnostics, contributing to wider adoption across biomedical research and clinical development.
Economic realities are also influencing these developments. Research published in the Journal of the National Cancer Institute Monographs reports that global spending on cancer medicines increased by 75 percent between 2020 and 2024, while worldwide cancer diagnoses are projected to rise substantially over the coming decades. As healthcare systems manage growing demand alongside expanding therapeutic options, greater emphasis is being placed on directing treatments toward patients with the highest likelihood of benefit. Precision oncology therefore represents both a scientific opportunity and an important consideration for long-term healthcare sustainability.
Read More on Essays
Recent developments across the global medical community illustrate how widely this conversation has expanded. The World Health Assembly recently endorsed a resolution supporting the responsible integration of precision medicine into health systems, while discussions at the 2026 American Society of Clinical Oncology (ASCO) Breakthrough Meeting highlighted biomarker-driven treatment selection, AI-assisted decision support, and molecular profiling as major priorities for the future of cancer care. Collectively, these developments suggest that precision oncology is evolving from a specialized field into a broader framework for clinical decision-making.
Within this landscape, Allarity Therapeutics CEO Thomas H. Jensen believes the next significant advance in oncology may come from improving how patients are matched with therapies. “The future of precision oncology depends on understanding the biology of each patient’s cancer without forcing the data to fit our expectations,” he says.
Jensen argues that decades of innovation have delivered valuable therapeutic options, while the next opportunity may lie in identifying which patients are most likely to benefit from those existing medicines. In his view, patient selection deserves equal attention alongside drug development because the greatest clinical value often emerges when both evolve together.
That perspective reflects years of work across bioinformatics, molecular biology, and companion diagnostics. Jensen observes that cancer biology rarely follows the simplified pathways often presented in textbooks. He notes that numerous molecular interactions may occur simultaneously inside a tumor cell, making single-gene explanations difficult to generalize across diverse patient populations. He also warns that confirmation bias can emerge when researchers search for evidence supporting existing assumptions instead of allowing large biological datasets to reveal unexpected patterns. Independent validation across separate patient populations, he believes, remains essential for developing reliable predictive tools.
These observations also influence how clinical outcomes are evaluated. Jensen emphasizes that overall survival provides one of the most meaningful indicators of patient benefit because it reflects outcomes that matter most to patients and clinicians. Tumor response remains an important clinical measurement, yet biological complexity sometimes produces differences between response rates and overall survival. “Every treatment decision represents time in a patient’s life,” Jensen says. “The greatest progress comes from identifying the therapy that offers the strongest opportunity for meaningful benefit before valuable time is lost.”
This philosophy informs the work being conducted at Allarity Therapeutics through its Drug Response Predictor platform, which analyzes gene-expression patterns to estimate which patients may respond to specific therapies. Jensen views this type of companion diagnostic as part of a broader movement toward more individualized oncology, where molecular information complements physician expertise during treatment selection. The company’s ongoing development of stenoparib for advanced ovarian cancer illustrates this broader concept.
Early clinical studies have explored stenoparib as a targeted cancer drug that blocks two key pathways tumors use to grow, showing a promising ability to shrink or stabilize tumors and extend survival in women with advanced ovarian cancer when patient selection is guided by a personalized genetic test. Jensen believes these types of studies contribute to a wider discussion about improving therapeutic precision throughout oncology.
Artificial intelligence is also expected to expand its role as larger biological datasets become available. Jensen sees considerable opportunity for AI while emphasizing that meaningful results depend on the quality of underlying clinical and molecular data. He also points to practical considerations such as standardized biopsy handling, laboratory workflows, and access to high-quality genomic and transcriptomic information as important elements supporting wider adoption of precision oncology. In his experience, technological progress and clinical infrastructure advance most effectively when they evolve together.
The future of cancer care will likely reflect continued collaboration among clinicians, researchers, diagnostic developers, and technology innovators. Precision oncology represents an expanding effort to combine biological insight with data science so treatment decisions become increasingly informed by each patient’s unique disease characteristics.
As healthcare systems continue investing in precision medicine, conversations will increasingly focus on translating scientific advances into practical clinical benefit. Matching the right therapy to the right patient has become an increasingly important objective across oncology, contributing to a future where personalized treatment decisions continue to advance alongside medical innovation.
View 0 Comments
Submit Correction
View Editorial & AI Guidelines